Allergan To Discuss Tazoral Psoriasis Non-Inferiority Study With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA deems oral tazarotene "not approvable." In addition to a non-inferiority study, Allergan must develop an "acceptable" risk management program and resolve manufacturing problems.